Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
PHASE2/PHASE3
60 participants
INTERVENTIONAL
2020-08-01
2021-08-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Sofosbuvir and ledipsavir
Sofosbuvir and ledipsavir plus standard of care treatment.
Sofosbuvir ledipsavir
Sofosbuvir ledipsavir once daily
Sofosbuvir and Daklatasuvir
Sofosbuvir and Daklatasuvir plus standard of card treatment..
sofosbuvir
Sofosbuvir once daily
Daclatasvir
Daklatasuvir tablets
Standard treatment
Standard treatment alone
No interventions assigned to this group
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
sofosbuvir
Sofosbuvir once daily
Sofosbuvir ledipsavir
Sofosbuvir ledipsavir once daily
Daclatasvir
Daklatasuvir tablets
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Tanta University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Sherief Abd-Elsalam
Ass. Prof. Tropical Medicine
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Marwa Salama, Consultant
Role: PRINCIPAL_INVESTIGATOR
Tanta University - Faculty of Medicine
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Sherief Abd-Elsalam
Tanta, , Egypt
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Sherief Abd-Elsalam, Ass. Prof.
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
sofosbuvir
Identifier Type: -
Identifier Source: org_study_id